15-year remission in refractory FLT3-mutated AML attained by sorafenib

IF 3 3区医学 Q2 HEMATOLOGY

Annals of Hematology Pub Date : 2024-09-25 DOI:10.1007/s00277-024-06012-3

Christoph Rummelt, Dietmar Pfeifer, Ralph Wäsch, Robert Zeiser, Justus Duyster, Jürgen Finke, Michael Lübbert

引用次数: 0

查看原文本刊更多论文

索拉非尼治疗难治性FLT3突变急性髓细胞白血病15年取得缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Hematology 医学-血液学

CiteScore

5.60

自引率

2.90%

发文量

304

审稿时长

2 months

期刊介绍： Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology.